Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

Exclusion Criteria

• •Need for hospitalization or immediate medical attention in the clinical opinion of the study investigator.
• •History of or current hospitalization for COVID-19.
• •History of ventricular arrhythmia or use of antiarrhythmics within 30 days prior to entry.
• •Personal or family history of Long QT syndrome.
• •History of kidney disease.
• •History of ischemic or structural heart disease.
• •History of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation
• •Personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (G6PD) deficiency.
• •Used drugs with possible anti-SARS-CoV-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis.
• •Requirement or expected requirement for a medication that significantly prolongs QT intervals or increases risk for QT prolongation.
• •Loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry.
• •Participated in a study where co-enrollment was not allowed.
• •Receipt of a SARS-CoV-2 vaccination prior to study entry.
• •Known allergy/sensitivity or any hypersensitivity to components of HCQ, azithromycin, or their formulation.
• •More than 10 days of any of the following symptoms attributed to the SARS-CoV-2 infection at study entry:
• •* Fever (can be subjective) or feeling feverish
• •* Cough
• •* Shortness of breath or difficulty breathing at rest or with exertion
• •* Sore throat
• •* Body pain or muscle pain
• •* Fatigue
• •* Headache
• •* Chills
• •* Nasal obstruction or congestion
• •* Loss of taste or smell
• •* Nausea or vomiting
• •* Diarrhea